Digital Payment Today - South Africa Embraces Fintech Innovations Amidst Tech Advancements
Elsewhere in the market, was a standout up 4.5% and closing at $46.10, close to the 52-week high. At the same time, softened, down 7.4% to end the day at IDR3,360.00, at its 52-week low.
Bank Rakyat Indonesia (Persero) expects enhanced profitability from strategic advantages and economic growth. Click to explore the detailed narrative on the bank's investment potential.
settled at $14.47 up 2.8%.
closed at $71.05 up 0.5%.
settled at $10.75 down 4.4%.
Jump into our full catalog of 188 Digital Payment Stocks, which includes ABN AMRO Bank, Powszechna Kasa Oszczednosci Bank Polski Spólka Akcyjna and Bank of Baroda, here.
Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Sources:
Simply Wall St
"South Africa's AI & Fintech Boom: Key Insights from 2025 Tech Trends Report" from Research and Markets on GlobeNewswire (published 27 February 2025)
Companies discussed in this article include NYSE:BAC NasdaqGS:SOFI NasdaqGS:PYPL NYSE:NU and IDX:BBRI.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Norwegian Cruise Line Sees Record Advance Ticket Sales, Reaffirms Profit Outlook
Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) on Thursday reported mixed results for its second quarter. Strong consumer demand continued to drive performance, largely meeting adjusted earnings expectations. The company also reaffirmed its full-year 2025 financial guidance. The cruise operator reported record revenue of $2.52 billion for the quarter, a 6% increase year-over-year (YoY), which missed the average analyst estimate of $2.55 billion. Norwegian Cruise Line Holdings reported GAAP net income of $30 million, or 7 cents per share. After adjusting for non-recurring costs, earnings were 51 cents per share, which is in line with the analyst estimate. Also Read: The company's second quarter saw a significant rebound from a softer first quarter, which was impacted by increased dry-dock capacity. Net Yield increased 3.1% in constant currency, exceeding guidance of 2.5%. Adjusted EBITDA for the quarter reached $694 million (+18% YoY), surpassing the company's guidance of $670 million. As of June 30, Norwegian Cruise Line Holdings reported total debt of $13.8 billion and net debt of $13.6 billion. The company improved its net leverage to 5.3x from 5.7x at the end of the first quarter. Liquidity stood at $2.4 billion, bolstered by the successful upsizing of its revolving loan facility to approximately $2.5 billion. Second-quarter occupancy was 103.9%, which is in line with guidance. Advance ticket sales hit a record high of $4.0 billion. View more earnings on NCLH Operational efficiency improved, with Gross margin per Capacity Day increasing 11% (12% in constant currency) compared to the previous year. Gross Cruise Costs per Capacity Day decreased to $306 from $315 in the prior year. Adjusted Net Cruise Cost excluding Fuel per Capacity Day remained flat in constant currency at approximately $163, outperforming guidance due to the timing of cost savings initiatives. 'Demand has rebounded across all three of our brands, with bookings now ahead of historical levels in recent months and continued strength in onboard spend. This performance reflects the strength of our offerings across the fleet, along with our disciplined focus on driving both return on investment and return on experience,' commented Harry Sommer, president and chief executive officer. Outlook Norwegian Cruise Line expects its third-quarter adjusted earnings to be $1.14 per share, falling short of the $1.18 analyst estimate. The company projects third-quarter occupancy to be approximately 105.5%. For the full year 2025, Norwegian Cruise Line Holdings reaffirmed its adjusted EPS guidance of $2.05, above the $2.03 analyst estimate. The company expects full-year net yield on a constant currency basis to increase approximately 2.5%, with occupancy projected at 103.0%. Adjusted EBITDA for the full year is still expected to be roughly $2.72 billion. The company is advancing several strategic initiatives, including the further expansion of Great Stirrup Cay, its private island in the Bahamas, featuring the nearly six-acre Great Tides Waterpark slated to open in summer 2026. In terms of fleet modernization and growth, Norwegian took delivery of Oceania Allura, the eighth ship for the Oceania Cruises brand, and underscored its long-term growth strategy by confirming orders for two additional next-generation Sonata Class Ships, with deliveries scheduled for 2032 and 2035. Price Action: NCLH shares are trading higher by 12% to $26.22 at last check Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Norwegian Cruise Line Sees Record Advance Ticket Sales, Reaffirms Profit Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion
Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year. U.S. sales slipped 3% to $8.5 billion, while international revenues climbed 10% to $3.8 billion, representing an 8% increase when excluding foreign exchange impacts (Ex-FX). Growth Portfolio revenues of $6.6 billion increased 18%, or 17% Ex-FX. Revenue growth was primarily driven by the immuno-oncology (IO) portfolio, Breyanzi, Reblozyl, and Camzyos, reflecting the continued strength of Cobenfy (a schizophrenia drug).Sales of the cancer drug Opdivo increased 7% to $2.56 billion. The arthritis drug Orencia generated sales of $963 million, up 2%. Sales of another cancer drug, Yervoy, increased 16% to $728 million. Camzyos (a heart drug) generated sales of $260 million, up 87%. The anemia drug Reblozyl generated $568 million in quarter sales, up 34% from a year ago. Legacy Portfolio revenues of $5.7 billion decreased 14%, or 15% Ex-FX. Demand increased for Eliquis, offset by expected continued generic impact across the remainder of the Legacy Portfolio and the impacts from the U.S. Medicare Part D redesign. View more earnings on BMY Bristol-Myers reported adjusted earnings of $1.46 per share, missing the consensus of $1.58. GAAP EPS was 64 cents and non-GAAP EPS was $1.46. Both figures include the net impact of 57 cents due to the Acquired IPRD charge associated with the BioNTech SE (NASDAQ:BNTX) strategic partnership worth $11 billion. Gross margin decreased from 73.2% to 72.5% on a GAAP basis, and from 75.6% to 72.6% on a non-GAAP basis, primarily due to product mix. Outlook Bristol Myers Squibb lowered its fiscal 2025 adjusted earnings guidance from $6.70-$7.00 to $6.35-$6.65 per share compared to the consensus of $6.76. The US drugmaker raised 2025 sales guidance from $45.8 billion-$46.8 billion to $46.5 billion-$47.5 billion compared to the consensus of $46.23 billion. It reiterated gross margin guidance of around 72%. On Monday, Bristol Myers and Bain Capital announced the creation of a new independent biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with five immunology assets in-licensed from Bristol Myers and a $300 million financing commitment that Bain Capital led. Price Action: BMY stock is trading lower by 3.04% to $44.58 at last check Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? BRISTOL-MYERS SQUIBB (BMY): Free Stock Analysis Report This article Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15 minutes ago
- Business Wire
Global Partners LP Announces Availability of 2024 Schedule K-3
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the 'Partnership') today announced that its 2024 Schedule K-3 reflecting items of international tax relevance is available online. Unitholders requiring this information may access their Schedule K-3 at A limited number of unitholders (primarily foreign unitholders, unitholders computing a foreign tax credit on their tax return and certain corporate and/or partnership unitholders) may need the detailed information disclosed on Schedule K-3 for their specific reporting requirements. To the extent Schedule K-3 is applicable to your federal income tax return filing needs, the Partnership encourages you to review the information contained on this form and refer to the appropriate federal laws and guidance or consult with your tax advisor. The Partnership is not planning to mail copies of the Schedule K-3 to investors. To receive an electronic copy of your Schedule K-3 via email, unitholders may call Tax Package Support toll free at (866) 867-4075 weekdays between 8 a.m. and 5 p.m. CT. About Global Partners LP Building on a legacy that began more than 90 years ago, Global Partners has evolved into a Fortune 500 company and industry-leading integrated owner, supplier, and operator of liquid energy terminals, fueling locations, and guest-focused retail experiences. Global operates or maintains dedicated storage at 54 liquid energy terminals—with connectivity to strategic rail, pipeline, and marine assets—spanning from Maine to Florida and into the U.S. Gulf States. Through this extensive network, the company distributes gasoline, distillates, residual oil, and renewable fuels to wholesalers, retailers, and commercial customers. In addition, Global owns, operates and/or supplies approximately 1,700 retail locations across the Northeast states, the Mid-Atlantic, and Texas, providing the fuels people need to keep them on the go at their unique guest-focused convenience destinations. Recognized as one of Fortune's Most Admired Companies, Global Partners is embracing progress and diversifying to meet the needs of the energy transition. Global Partners, a master limited partnership, trades on the New York Stock Exchange under the ticker symbol 'GLP.' For additional information, visit
